Perkins Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.34M | Sell |
5,307
-35
| -0.7% | -$7.53K | 1% | 26 |
|
|
2026
Q1 | $1.16M | Sell |
5,342
-500
| -9% | -$111K | 1.09% | 27 |
|
|
2025
Q4 | $1.33M | Hold |
5,842
| – | – | 1.06% | 27 |
|
|
2025
Q3 | $1.35M | Sell |
5,842
-50
| -0.8% | -$10.2K | 1.19% | 25 |
|
|
2025
Q2 | $1.09M | Sell |
5,892
-338
| -5% | -$62.8K | 1.1% | 28 |
|
|
2025
Q1 | $1.31M | Sell |
6,230
-78
| -1% | -$15.2K | 1.38% | 21 |
|
|
2024
Q4 | $1.12M | Sell |
6,308
-250
| -4% | -$46K | 0.99% | 34 |
|
|
2024
Q3 | $1.3M | Sell |
6,558
-1,425
| -18% | -$266K | 1.21% | 26 |
|
|
2024
Q2 | $1.37M | Sell |
7,983
-525
| -6% | -$87K | 1.29% | 23 |
|
|
2024
Q1 | $1.55M | Sell |
8,508
-650
| -7% | -$112K | 1.29% | 24 |
|
|
2023
Q4 | $1.42M | Sell |
9,158
-1,700
| -16% | -$248K | 1.21% | 25 |
|
|
2023
Q3 | $1.62M | Sell |
10,858
-150
| -1% | -$22K | 1.6% | 19 |
|
|
2023
Q2 | $1.48M | Sell |
11,008
-500
| -4% | -$73.3K | 1.29% | 29 |
|
|
2023
Q1 | $1.83M | Sell |
11,508
-100
| -0.9% | -$15.3K | 1.73% | 17 |
|
|
2022
Q4 | $1.88M | Hold |
11,608
| – | – | 1.98% | 16 |
|
|
2022
Q3 | $1.56M | Sell |
11,608
-417
| -3% | -$59.8K | 1.74% | 20 |
|
|
2022
Q2 | $1.84M | Hold |
12,025
| – | – | 1.91% | 18 |
|
|
2022
Q1 | $1.95M | Hold |
12,025
| – | – | 1.6% | 24 |
|
|
2021
Q4 | $1.63M | Sell |
12,025
-288
| -2% | -$34K | 1.1% | 32 |
|
|
2021
Q3 | $1.33M | Hold |
12,313
| – | – | 0.82% | 40 |
|
|
2021
Q2 | $1.39M | Hold |
12,313
| – | – | 0.79% | 42 |
|
|
2021
Q1 | $1.33M | Buy |
12,313
+125
| +1% | +$13.4K | 0.77% | 46 |
|
|
2020
Q4 | $1.31M | Sell |
12,188
-900
| -7% | -$86.5K | 0.85% | 39 |
|
|
2020
Q3 | $1.15M | Buy |
+13,088
| New | +$1.23M | 1.05% | 33 |
|
|
2020
Q1 | $1.09M | Sell |
14,338
-200
| -1% | -$17K | 1.32% | 26 |
|
|
2019
Q4 | $1.29M | Sell |
14,538
-2,450
| -14% | -$203K | 1.15% | 28 |
|
|
2019
Q3 | $1.29M | Buy |
16,988
+6,038
| +55% | +$414K | 1.11% | 33 |
|
|
2019
Q2 | $796K | Buy |
10,950
+200
| +2% | +$15.7K | 0.56% | 53 |
|
|
2019
Q1 | $866K | Buy |
+10,750
| New | +$879K | 0.57% | 54 |
|
|
2018
Q1 | – | Sell |
-20,300
| Closed | -$1.96M | – | 118 |
|
|
2017
Q4 | $1.96M | Buy |
20,300
+750
| +4% | +$70.7K | 1.89% | 9 |
|
|
2017
Q3 | $1.74M | Sell |
19,550
-100
| -0.5% | -$7.61K | 1.82% | 14 |
|
|
2017
Q2 | $1.43M | Sell |
19,650
-25
| -0.1% | -$1.68K | 1.58% | 17 |
|
|
2017
Q1 | $1.28M | Buy |
19,675
+2,150
| +12% | +$135K | 1.32% | 19 |
|
|
2016
Q4 | $1.1M | Sell |
17,525
-250
| -1% | -$15.3K | 1.2% | 25 |
|
|
2016
Q3 | $1.12M | Buy |
17,775
+300
| +2% | +$19.4K | 1.12% | 31 |
|
|
2016
Q2 | $1.08M | Sell |
17,475
-1,000
| -5% | -$60.9K | 1.24% | 26 |
|
|
2016
Q1 | $1.05M | Hold |
18,475
| – | – | 1.32% | 24 |
|
|
2015
Q4 | $1.09M | Sell |
18,475
-100
| -0.5% | -$5.76K | 1.17% | 26 |
|
|
2015
Q3 | $1.01M | Buy |
18,575
+750
| +4% | +$48.8K | 1.12% | 28 |
|
|
2015
Q2 | $1.2M | Sell |
17,825
-50
| -0.3% | -$3.26K | 1.05% | 29 |
|
|
2015
Q1 | $1.05M | Buy |
17,875
+100
| +0.6% | +$6.04K | 0.88% | 39 |
|
|
2014
Q4 | $1.16M | Buy |
17,775
+900
| +5% | +$56.7K | 1% | 39 |
|
|
2014
Q3 | $975K | Buy |
+16,875
| New | +$937K | 0.82% | 43 |
|
Other funds holding ABBV
Perkins Capital Management's ABBV Position: Q2 2026 in Review
Perkins Capital Management reduced its AbbVie (ABBV) stake by 0.66% in Q2 2026, selling an estimated $7.53K and leaving 5,307 shares worth $1.34M. The position accounts for 1% of the portfolio, ranked #26.
Perkins Capital Management first reported a position in ABBV in Q3 2014 and has held it in 43 quarters since. The position peaked at $1.96M in Q4 2017. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Perkins Capital Management held 5,307 shares of AbbVie worth $1.34M as of Q2 2026.
- Perkins Capital Management sold 35 AbbVie shares in Q2 2026, an estimated $7.53K.
- AbbVie made up 1% of Perkins Capital Management's portfolio in Q2 2026, its #26 holding.
- Perkins Capital Management first reported a position in AbbVie in Q3 2014 and has held it in 43 quarters since.
- Perkins Capital Management's AbbVie position peaked at $1.96M in Q4 2017.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.